|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||295.00 - 298.38|
|52 Week Range||249.17 - 370.57|
|PE Ratio (TTM)||21.16|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
PTC Therapeutics spiked Wednesday after an analyst suggested it and Roche could rout Biogen and Ionis Pharmaceuticals in treating spinal muscular atrophy.
Biogen and Ionis Crash on PTC Therapeutics' Promising DataPTC Therapeutics presented positive data on its SMA drug under trial
PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.
The S&P 500’s top losses on June 18 were: Biogen (BIIB) declined 5.2%. Comcast Corp A (CMCSA) declined 3.8%. AmerisourceBergen (ABC) declined 3.5%. Intel (INTC) declined 3.4%. CVS (CVS) declined 3.4%. Biogen
The Dow Jones Industrial Average dropped more than 100 points today but the loss wasn't nearly as bad as it could have been. For the past two days, the Dow Jones Industrial Average has started off with sizable selloffs, only to rally back. The S&P 500, meanwhile, has barely finished down on those days, and today the Nasdaq Composite didn't even drop.
Biogen tumbled 6 percent on Monday, after a rival drugmaker reported its experimental drug for spinal muscular atrophy helped a majority of babies who received it. Biogen has a few new drugs in the pipeline, including one that could help the company defend its leadership in MS drug therapy, but these are at least two years away reaching the market. Biogen BIIB tumbled as much as 6 percent on Monday, after a rival drugmaker reported its experimental drug for spinal muscular atrophy helped a majority of babies who received it.
PTC Therapeutics Inc. shares rose to their highest price since August 2015 after the company said its experimental drug for spinal muscular atrophy helped the vast majority of babies who got the treatment. Over the weekend the company reported that after 182 days of treatment, 91 percent of babies on the drug improved more than four points on a scale that measures motor milestone developments in patients with a form of spinal muscular atrophy, or SMA. Spinal muscular atrophy is a rare disease that progressively takes away people’s physical strength and their ability to walk, eat and breathe.
Stocks slid lower Monday as global markets remained rattled by the U.S.-China trade standoff. China stocks were highly active, however, led by JD.com.
Biogen Inc (NASDAQ:BIIB) is trading with a trailing P/E of 21.9x, which is lower than the industry average of 28.7x. While BIIB might seem like an attractive stock to buy,Read More...
The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.
Alzheimer’s disease ruins lives. As people live longer, more lives will be ruined every passing year. The brain disorder has done just as much damage to the hopes of medical researchers. While some drugs ...
Biogen (BIIB) completed a pact to collaborate with Ionis Pharmaceuticals (IONS), and bought 11.5 million Ionis shares for $625 million, paying $54.34 each. Biogen also invested $375 million as an upfront payment to Ionis to "jointly discover and develop novel antisense drugs for a broad range of neurological diseases," as stated in a press release. In total, Biogen laid out $1 billion in cash.
Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.
Gilmore O’Neill’s exit from Biogen comes at a particularly inopportune moment for the company, which is testing a potential Alzheimer’s treatment in late-stage studies.
Biogen Inc. said Thursday it has entered an exclusive option agreement with TMS Co. Ltd. to acquire its TMS-007 treatment for acute stroke. "TMS-007 is a plasminogen activator with a novel mechanism of action associated with breaking down blood clots, and is believed to inhibit local inflammation at the site of thrombosis," Biogen said in a statement. The drug has the potential to extend the treatment window compared with current thrombolytic agents, it said.
The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.
Generally speaking, pharmaceuticals are experiencing a mixed year. After a promising start where Biogen shares closed out January up more than 8%, the momentum quickly collapsed. It wasn’t until the prior month that BIIB stock began to recover from its mess.
Biogen Inc's ( BIIB) stock has rebounded sharply over the past few weeks, with the stock rising by over 14% since April 23. The stock has struggled in 2018, with shares down by nearly 20% from their highs in late January and for a good reason. Biogen shares have risen to a technical resistance level at $300 and have failed to rise above that resistance level.